Precision BioSciences, Inc. (DTIL) announced on March 02, 2026 that it has received a $7.5 million milestone payment from TG Therapeutics, Inc. (TGTX) for progress in the azer‑cel Phase 1 clinical trial of the multiple sclerosis therapy.
The payment was triggered by the achievement of a predefined milestone under the two‑year license agreement between the companies, which grants Precision the right to develop and commercialize azer‑cel in the United States and Canada. The milestone represents a significant cash inflow for Precision, which is currently operating on a limited cash runway as it advances its ARCUS‑based gene‑editing programs.
This milestone payment underscores the commercial potential of Precision’s ARCUS platform and provides additional financial flexibility as the company continues to pursue its in‑vivo gene‑editing pipeline. The transaction also reinforces the partnership with TG Therapeutics, which has licensed Precision’s technology for other indications beyond multiple sclerosis.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.